Ascendis Pharma Files 6-K Report
Ticker: ASND · Form: 6-K · Filed: Dec 12, 2024 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, 6-K, routine-report
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a routine 6-K, nothing new to see here.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on December 12, 2024, to report its activities for the month of December 2024. The filing is a routine report for foreign private issuers and incorporates by reference into several existing registration statements on Form S-8.
Why It Matters
This filing provides an update on Ascendis Pharma's ongoing reporting obligations as a foreign private issuer, which is important for investors tracking company disclosures.
Risk Assessment
Risk Level: low — This is a standard SEC filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 0001193125-24-277035 (filing_id) — Accession Number
- 20241212 (date) — Filing Date
- Tuborg Boulevard 12 DK-2900 Hellerup Denmark (address) — Principal Executive Offices
FAQ
What type of SEC filing is this?
This is a Form 6-K report of a foreign private issuer.
Who is the filer of this report?
The filer is Ascendis Pharma A/S.
What is the filing date of this report?
The filing date is December 12, 2024.
What is the company's principal executive office address?
The address is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
What other SEC filings does this report incorporate by reference?
This report incorporates by reference into registration statements on Form S-8, specifically including Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, and 333-216883.
Filing Stats: 844 words · 3 min read · ~3 pages · Grade level 19.4 · Accepted 2024-12-12 16:05:12
Filing Documents
- d862935d6k.htm (6-K) — 14KB
- 0001193125-24-277035.txt ( ) — 15KB
Forward-Looking Statements
Forward-Looking Statements This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding Ascendis future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the PDUFA goal date for SKYTROFA. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis products and product candidates; unforeseen safety or efficacy results in Ascendis development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: December 12, 2024 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer